T2 BIOSYSTEMS, INC. (NASDAQ:TTOO) Files An 8-K Results of Operations and Financial Condition
Item 2.02 Results of Operations and Financial Condition
On March 7, 2019, T2 Biosystems, Inc. (the Company) issued a press release announcing its financial results for its fiscal quarter and year ended December31, 2018 and held a conference call to discuss those results. A copy of the Companys press release and a copy of the transcript of the conference call are furnished with this report as Exhibits 99.1 and 99.2, respectively.
In accordance with General Instruction B.2 of Form 8-K, the information in this Item 2.02 and Exhibits 99.1 and 99.2 of this Current Report on Form 8-K are being furnished and shall not be deemed to be filed for purposes of Section18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section. Furthermore, such information, including Exhibits 99.1 and 99.2 attached hereto, shall not be deemed to be incorporated by reference in any filing under the Securities Act of 1933, as amended, except as expressly stated by specific reference in such a filing.
Item 2.02 Financial Statements and Exhibits
(d) Exhibits
| Transcript of conference call held by T2 Biosystems, Inc. on March7, 2019 |
T2 Biosystems, Inc. Exhibit
EX-99.1 2 d682740dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 T2 Biosystems Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Corporate Update Secured 14 New Instrument Contracts in the Fourth Quarter and 39 total New Instrument Contracts in 2018 that are expected to drive growth in Recurring Test Revenue Confirms Guidance of a Doubling of Revenue in 2019; Provides Guidance of Securing 70 – 80 T2Dx Instruments Contracts in 2019 LEXINGTON,…
To view the full exhibit click here
About T2 BIOSYSTEMS, INC. (NASDAQ:TTOO)
T2 Biosystems, Inc. is an in vitro diagnostics company engaged in developing a technology platform offering an alternative to diagnostic methodologies. The Company’s T2 Magnetic Resonance platform (T2MR) enables detection of pathogens, biomarkers and other abnormalities in a range of unpurified patient sample types, including whole blood, plasma, serum, saliva, sputum and urine, and can detect cellular targets at limits of detection as one colony forming unit per milliliter (CFU/mL). The Company’s initial development efforts target sepsis, hemostasis and Lyme disease. T2MR is a miniaturized, magnetic resonance-based approach that measures how water molecules react in the presence of magnetic fields. Its platform detects a range of targets, including molecular targets, such as deoxyribonucleic acid (DNA), immunodiagnostics, such as proteins, and a range of hemostasis measurements. The Company offers T2Dx Instrument (T2Dx) and the T2Candida Panel.
